8-K - Alto Neuroscience, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Alto Neuroscience reported that ALTO-101 did not achieve statistical significance on primary endpoints in its Phase 2 CIAS study, leading the company to prioritize ALTO-207 and explore partnering for ALTO-101.

Key Takeaways

1ALTO-101 failed to achieve statistical significance on primary EEG or cognitive endpoints in Phase 2 CIAS study, though directional improvements were observed.

2Company will not independently advance ALTO-101 in CIAS, instead prioritizing resources toward lead program ALTO-207.

3Alto plans to explore strategic partnering opportunities for ALTO-101, particularly for its modified-release oral formulation.

4ALTO-207 remains on track to initiate Phase 2b trial in first half of 2026 for treatment-resistant depression.

5Company reported $275 million cash position as of the filing date.

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

| Other Events. | |---|---| On April 1, 2026, Alto Neuroscience, Inc. issued a press release entitled “Alto Neuroscience Reports Topline Data from Phase 2 Proof

Other Event

9.01

| Financial Statements and Exhibits. | |---|---| (d) Exhibits. Exhibit No.: 99.1 | Description: Press Release of Alto Neuroscience, Inc. Exhibit No.: 104 | Desc

Exhibits Only

Source Document

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1